Rajagopalan, S., Andreeva, A., Rutherford, T
NICE NG28 recommends prioritising SGLT-2 inhibitors in people with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease often alongside or instead of metformin due to these organ-protective effects [10] [8] GLP-1 receptor agonists (e.g., semaglutide, liraglutide) generally produce greater HbA1c reductions (1.01.5%) and significant weight loss, but are injectable and more costly
In other investigated variables, extending supplementation duration was ineffective in the overall results
[ Links ] 16
Ongoing clinical trials Some doctors are already prescribing GLP-1 drugs off-label for substance use disorders
extended this approach to examine the effects of clenbuterol and salbutamol on pork tissue metabolism (Lu et al., 2017)